September 26, 2025 | Pharma Tariff Shock, Broad Selloff, and Critical Support Test

Feedback on Morning Newsletter

The morning brief anticipated a soft to flat start with GIFT Nifty hovering near 24,900, but the session unfolded with sharper downside than projected. The impact of proposed US pharmaceutical tariffs materialized more severely than expected, with the pharma sector declining 2.2%, exceeding our cautious stance.

Key validation

• Morning expectation: Nifty soft start near 24,900
• Actual outcome: Nifty opened weak and closed at 24,654.70 (Official)
• Deviation: ~245 points worse than morning expectations

Subscriber feedback synthesis highlighted concerns around the cascading impact of US pharma tariffs and their implications for India’s $10.5B pharmaceutical exports to the US.

From October 1, 2025, the United States plans to impose a 100% tariff on branded or patented pharmaceutical imports, with exemptions for companies that have already initiated US manufacturing. Generics are not targeted. For Indian pharma, direct exposure remains concentrated in specialty and branded portfolios, while API-focused firms face limited direct risk. Indirect effects through sourcing and partner behavior remain key watch items.

Key Movements in Indian Equity Markets

Validated closes (26-Sep-2025)

• Nifty 50: 24,654.70 (-236.15 pts, -0.95%)
• Sensex: 80,426.46 (-733.22 pts, -0.90%)
• Bank Nifty: 54,389.35 (-586.85 pts, -1.07%)

All major sectoral indices closed lower, reflecting broad-based selling pressure.

• IT: -2.3%
• Pharma: -2.2%
• Banking: -1.0%

Weakness was driven by tariff uncertainty, sustained FII outflows, and continued rupee pressure.

Under-Reported Market Patterns

Despite the seventh consecutive decline, Nifty is only ~5.5% below its September 2024 peak, indicating index-level resilience compared to individual stocks, where 485 mid- and small-cap names are down over 20%.

A notable micro-pattern emerged: selling intensity clustered in high US-exposure cohorts (large-cap IT and export-oriented pharma), while select domestic cyclicals held relatively steadier on a beta-adjusted basis. External-shock beta dominated domestic-demand beta during the session.

Technical Levels Analysis

• Nifty support: 24,600–24,650 (tested and held intraday)
• Nifty resistance: 24,850–24,900 (previous support turned resistance)
• Bank Nifty: 54,000 remains a critical psychological level

Economic Data & FX

INR/USD

• FBIL reference: 88.67 (25-Sep-2025, latest available)
• Spot / futures: ~88.72 (Provisional)

The rupee continues to trade near record-weak zones, pressured by sustained FII outflows.

Institutional flows (provisional)

• FII cash: -₹4,995.42 crore (25-Sep)
• DII activity: ₹17,064.63 crore (26-Sep)

Market Sentiment Indicators

• Put-Call Ratio: Hovering near oversold territory, indicating scope for a technical bounce despite macro headwinds
• India VIX: Elevated, reflecting heightened uncertainty around US trade policy
• Breadth: Severely negative — only 8 Nifty 50 stocks advanced versus 42 declines

Data-Driven Trade Ideas (educational only)

Top stocks to watch

1. L&T — Infrastructure resilience; top Nifty gainer
2. Tata Motors — Recovery after JLR cyber-attack resolution
3. Sun Pharma — At 52-week low; value opportunity post tariff clarity
4. Maruti Suzuki — 52-week high, auto sector relative strength
5. ITC — Defensive stability amid broader weakness

Options framework

• Bank Nifty iron condor in the 54,000–55,000 range
• Bear call spread on Nifty 25,000/25,200 to express resistance
• Protective puts near 24,600–24,700 given VIX uptick
• Prefer pharma pair trades over blanket shorts amid policy uncertainty

Educational Segment

Tariff Pass-Through
Tariff pass-through refers to how import duties translate into end-market pricing. In pharmaceuticals, companies must choose between absorbing margin pressure or accelerating US manufacturing investments to bypass tariffs.

Forward Outlook & Subscriber Engagement

Monday watch levels

• Nifty: Break below 24,600 opens 24,450–24,500
• Sensex: 80,000 psychological support
• Bank Nifty: Below 54,000 opens 53,600

Key catalysts

• US PCE inflation data
• Pharma sector guidance and policy responses

Compliance & Disclaimers

This newsletter is for informational and educational purposes only and does not constitute investment advice. Provisional data is subject to revision and will be reconciled in the next trading session. Market investments carry inherent risks, and past performance does not guarantee future results.

Proceed with titikṣā; conclude with upekṣā.

‍